Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
02 mai 2023 07h50 HE
|
Tenaya Therapeutics, Inc.
TN-201 Being Developed for the Potential Treatment of MYBPC3-associated HCM Dosing in Phase 1 Clinical Trial Expected to Commence in Q3 2023 SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE...
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
09 déc. 2022 06h45 HE
|
BioNTech SE
NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug...
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
23 août 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma
08 mars 2022 17h32 HE
|
7 Hills Pharma
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
15 déc. 2020 08h30 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
30 nov. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Vacaville Establishes Fast Track Program for Biotechnology Projects
19 nov. 2020 11h15 HE
|
City of Vacaville
VACAVILLE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- The City of Vacaville, which last month unveiled plans for the next generation of development of its world-class biomanufacturing cluster, has...
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
13 oct. 2020 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
12 juin 2020 08h30 HE
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
21 mai 2020 16h01 HE
|
Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...